What Is Cagrilintide? A Research Overview

Cagrilintide is an investigational long-acting amylin analog used as a reference compound in laboratory metabolic research, where it is often studied alongside the GLP-1 analog semaglutide. Any Bolt Peptide material referenced here is supplied only for controlled in-vitro laboratory research by qualified professionals and is not for human or veterinary use.

Quick facts

• Class: long-acting amylin analog (amylin/calcitonin receptor agonist)
• Status: investigational — not FDA-approved
• Research focus: metabolic research
• Form: lyophilized powder for laboratory research use only

What is Cagrilintide?

Cagrilintide is a synthetic peptide analog of human amylin, a hormone co-secreted with insulin. Native amylin is chemically unstable and prone to forming amyloid fibrils, which makes it difficult to study. Cagrilintide was engineered as a stabilized, lipidated analog with a substantially longer duration of action than earlier amylin-based compounds — a property that has made it a useful tool compound for laboratory and clinical metabolic research [1]. In research settings it is frequently examined both on its own and in combination with semaglutide.

What does the research show?

Published phase 2 literature evaluates cagrilintide and semaglutide across controlled metabolic research endpoints [2]. This citation is included to document the experimental record; it does not translate a study population, route, amount, protocol, or reported endpoint into guidance or a claim for any Bolt material.

Mechanisms studied in the lab

• Amylin receptor signaling: preclinical work indicates cagrilintide acts through amylin receptors AMY1R and AMY3R, assembled from the calcitonin receptor together with receptor-activity-modifying proteins [3].
• Hindbrain activity: in animal models, cagrilintide activated neurons in hindbrain regions (area postrema and nucleus of the solitary tract) in a receptor-subtype-dependent manner [3].
• Calcitonin-family overlap: because amylin and calcitonin receptors share the calcitonin receptor core, researchers compare cagrilintide’s signaling profile with related calcitonin-family agonists to map receptor selectivity.

Research status and safety

Cagrilintide remains an investigational literature compound. Bolt Peptide reference material is intended only for controlled in-vitro laboratory and analytical research by qualified professionals. It is not for human or veterinary use or consumption.

Handling

Cagrilintide is supplied in lyophilized form. Qualified laboratory personnel must establish storage, solvent compatibility, material handling, and final concentration under an approved protocol and SOP. See the laboratory concentration and handling reference, review Cagrilintide product details, or browse related GLP research materials.

FAQ

What is CagriSema? CagriSema is research shorthand used in published literature for the combined study of cagrilintide and semaglutide. The term is presented only to describe the scientific record.

What is cagrilintide’s research status? It remains investigational in the published record. Bolt Peptide supplies only research-use-only reference material for controlled laboratory work.

How is cagrilintide different from pramlintide? Both are amylin-based peptides, but cagrilintide was engineered for greater stability and a longer duration of action, which is why it is used as a long-acting amylin tool compound in research.

References

1. Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021.
2. Frias JP, et al. Once-weekly cagrilintide with once-weekly semaglutide in type 2 diabetes: a phase 2 trial. Lancet. 2023.
3. Carvas AO, et al. Cagrilintide acts through brain amylin receptors 1 and 3. eBioMedicine. 2025.

For research use only. Not for human or veterinary use. Cagrilintide is investigational and not FDA-approved. Statements have not been evaluated by the FDA.